Cargando…
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Significant strides have been made in the management of patients living with myeloma. However, patients with multiply relapsed or refractory multiple myeloma (MM) have a shorter overall survival; therefore, new treatments with novel mechanisms of action are needed in this patient population. Patient...
Autores principales: | Catamero, Donna, Richards, Tiffany, Faiman, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342926/ https://www.ncbi.nlm.nih.gov/pubmed/35937467 http://dx.doi.org/10.6004/jadpro.2022.13.5.13 |
Ejemplares similares
-
A Focus on Relapsed Multiple Myeloma
por: Noonan, Kimberly, et al.
Publicado: (2022) -
A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022) -
A Focus on Special Populations in Relapsed Multiple Myeloma
por: Steinbach, Mary, et al.
Publicado: (2022) -
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
por: Lu, Rebecca, et al.
Publicado: (2022) -
The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy
por: Adkins, Sherry
Publicado: (2019)